Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioAge Labs
Biotech
BioAge axes obesity asset over liver toxicity
Weeks after stopping a phase 2 trial, the biotech has jettisoned the molecule and shifted its focus to a preclinical neuroinflammation prospect.
Nick Paul Taylor
Jan 28, 2025 10:11am
BioAge secures Novartis deal worth up to $550M biobucks
Dec 18, 2024 10:44am
BioAge obesity study derailed by side effects 2 months after IPO
Dec 9, 2024 4:36am
What can we learn from 2024’s biotech IPOs?
Dec 6, 2024 8:44am
Biophama VC, deal values and exits all rise in Q3: Pitchbook
Nov 20, 2024 6:15am
BioAge brings in $198M from IPO as obesity biotech joins Nasdaq
Sep 26, 2024 4:44am
